OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Sustained MRD negative remission in del17p and TP53 mutated B cell prolymphocytic leukemia with ibrutinib and venetoclax
Maria Siddiqui, Allyson Price, Alessandra Ferrajoli, et al.
Leukemia Research Reports (2021) Vol. 16, pp. 100266-100266
Open Access | Times Cited: 6
Maria Siddiqui, Allyson Price, Alessandra Ferrajoli, et al.
Leukemia Research Reports (2021) Vol. 16, pp. 100266-100266
Open Access | Times Cited: 6
Showing 6 citing articles:
Prolymphocytic Leukaemia: an Update on Biology and Treatment
Dima El‐Sharkawi, Claire Dearden
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 129-135
Closed Access | Times Cited: 1
Dima El‐Sharkawi, Claire Dearden
Current Oncology Reports (2024) Vol. 26, Iss. 2, pp. 129-135
Closed Access | Times Cited: 1
De-Novo B-Cell Prolymphocytic Leukemia
Sasmith Menakuru, Janet E. Roepke, Salahuddin Siddiqui
Journal of Hematology (2023) Vol. 12, Iss. 2, pp. 82-86
Open Access | Times Cited: 3
Sasmith Menakuru, Janet E. Roepke, Salahuddin Siddiqui
Journal of Hematology (2023) Vol. 12, Iss. 2, pp. 82-86
Open Access | Times Cited: 3
Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review
Prioty Islam
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 9, pp. 1259-1273
Closed Access | Times Cited: 3
Prioty Islam
Current Treatment Options in Oncology (2023) Vol. 24, Iss. 9, pp. 1259-1273
Closed Access | Times Cited: 3
Venetoclax induces deep and durable minimal residual disease‐negative remission in high‐risk TP53 disrupted B prolymphocytic leukaemia
Lucia Chen, Toby A. Eyre
European Journal Of Haematology (2022) Vol. 109, Iss. 5, pp. 590-592
Closed Access | Times Cited: 3
Lucia Chen, Toby A. Eyre
European Journal Of Haematology (2022) Vol. 109, Iss. 5, pp. 590-592
Closed Access | Times Cited: 3
Clinical analysis of prolymphoblastic leukemia: the rare hematological malignancy in the elderly.
Zhimin Yan, Minjuan Zeng, Xiaojun Chen, et al.
PubMed (2023) Vol. 15, Iss. 9, pp. 5653-5663
Closed Access
Zhimin Yan, Minjuan Zeng, Xiaojun Chen, et al.
PubMed (2023) Vol. 15, Iss. 9, pp. 5653-5663
Closed Access
[Clinical features and prognosis of eight patients with splenic diffuse red pulp small B-cell lymphoma].
X L Zhang, Jianxi Luo, J J Zhang, et al.
PubMed (2022) Vol. 43, Iss. 12, pp. 1028-1033
Closed Access
X L Zhang, Jianxi Luo, J J Zhang, et al.
PubMed (2022) Vol. 43, Iss. 12, pp. 1028-1033
Closed Access
